Biotech companies create drugs from living organisms, requiring a BLA for FDA approval. Pharma companies develop drugs from chemicals, needing an NDA for FDA approval. Many firms blend biotech and ...

Bloomberg Intelligence’s team of experienced biotech, pharma, policy and litigation analysts author exclusive, data-driven research that can help you pinpoint long-term market opportunities.

As the health impacts of climate change become harder to ignore, biotechnology and pharmaceutical companies are facing increasing pressure from investors, employees, and government regulators to ...

Investment in new, early-stage drugs is typically driven by the short-term needs of big pharmaceutical companies. When drugs go generic due to patent expirations, it can cost the big drugmakers ...

Big Pharma is investing heavily in AI to slash development timelines and foster innovation. But instead of strengthening future relationships with the biotech world, the investment may position ...

That is essentially the idea behind Roivant ROIV-0.64%decrease; red down pointing triangle, a biotech company with a handful of drugs it got from pharma’s dustbin. Roivant was founded by the ...

In this article, we are going to take a look at where BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) stands against other most profitable biotech stocks to buy right now. With improved market ...

As venture capitalists pull back on their funding for life sciences, Big Pharma is flexing its considerable financial muscle to grab up smaller biotech companies, providing an injection of ...

Biotech firms produce meds from organisms; pharma companies create drugs chemically. Biotechs file a BLA for FDA approval, while pharmas submit an NDA. Investors should assess management ...